May 20 (Reuters) - Sanofi on Friday won expanded U.S. approval for its best-selling Dupixent injection to treat an allergic inflammation of the esophagus, the U.S. Food and Drug Administration said. (Reporting by Ludwig Burger; Additional reporting by Eva Mathews; Editing by Maju Samuel)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
91.3 EUR | -0.65% | +0.08% | +1.72% |
May. 03 | GSK plc : Back on track | |
May. 02 | European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.72% | 123B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- SAN Stock
- News Sanofi
- Sanofi's Dupixent wins U.S. approval for bigger use